Hengrui Medicine executive compensation disclosure, average annual salary of 2.84 million

（Source: Antibody Circle）

Based on the latest annual report data from Hengrui, after excluding the independent directors, the chairman of the supervisory board, and the members of the supervisory board, Hengrui Pharmaceutical has 10 directors and senior executives.

In terms of age, the average age of Hengrui Pharmaceutical’s directors and senior executives is 56. Among them, Chairman and Executive Director Sun Piaoyang is the oldest at 68, and Board Secretary Liu Xiaohan is the youngest at 41.

In terms of compensation, the total remuneration received by the directors and senior executives is RMB 26.4498 million, with an average remuneration of RMB 2.8448 million, and the annual salary median is RMB 2.5092 million. Among them, the highest compensation is RMB 6.5362 million for General Manager (President), Executive Director, and Chief Operating Officer Feng Ji, while the lowest compensation is RMB 0.7533 million for Board Secretary Liu Xiaohan (the 2025 term was less than 1 year, so it is not included in the statistics).

TOP 8 Board Secretary Liu Xiaohan

Pre-tax annual salary: RMB 0.7533 million

Working at Hengrui since August 2011, he has served successively as Deputy Director of the Securities Legal Affairs Department of the company and as Securities Affairs Representative. He has served as Board Secretary since 2016. Compared with RMB 0.8507 million in 2024, his annual salary decreased by RMB 0.0974 million.

TOP 7 Chairman Sun Piaoyang

Pre-tax annual salary: RMB 2.0147 million

As the person steering Hengrui, Sun Piaoyang served as Chairman of the Board from April 1997 to January 2020, as a director from January 2020 to August 2021, and returned in August 2021 and has served as Chairman to date. His salary increased by RMB 0.3622 million compared with RMB 1.6525 million in 2024.

TOP 6 Senior Vice President Sun Jiping

Pre-tax annual salary: RMB 2.0505 million

He joined Hengrui in September 1998 and previously served as the company’s Chief Financial Officer. He has served as a director since January 2020. He served as Vice General Manager from April 2013 to December 2024, and has served as Senior Vice President since December 2024. His salary decreased by RMB 0.4295 million compared with RMB 2.48 million in 2024.

TOP 5 Chief Financial Officer Liu Jianjun

Pre-tax annual salary: RMB 2.5092 million

He previously served as Audit Partner at KPMG Huazhen Certified Public Accountants (Special General Partnership). He joined Hengrui in June 2021 as Deputy General Manager of a subsidiary, and has served as Chief Financial Officer since November 2021. His salary increased by RMB 0.2254 million compared with RMB 2.2838 million in 2024.

TOP 4 Executive Vice President Zhang Lianshan

Pre-tax annual salary: RMB 4.0373 million

He worked at Eli Lilly from March 1998 to July 2008, holding roles including Senior Chemist, Chief Research Scientist, and Research Consultant for multiple research projects. From August 2008 to April 2010, he served as Senior Director of Chemistry at the U.S. company MarcadiaBiotech. Since April 2012, he has served as a director of Hengrui. From August 2010 to December 2024, he served as Vice General Manager, and since December 2024, he has served as Executive Vice President of the company. His salary increased by RMB 1.37 million compared with RMB 3.9003 million in 2024.

TOP 3 Vice Chairman Dai Hongbin

Pre-tax annual salary: RMB 4.1423 million

He joined Hengrui in July 2000 and has served successively as Director of the Office and Board Secretary. He has served as a director since January 2020. He served as Vice General Manager from April 2013 to May 2022, as General Manager (President) from May 2022 to April 2025, and has served as Vice Chairman since April 2025. His salary decreased by RMB 7.347 million compared with RMB 4.877 million in 2024.

TOP 2 Executive Vice President Jiang Ningjun

Pre-tax annual salary: RMB 4.4063 million

Between 2000 and 2016, he served as Head of the Cardiology Clinical Research Team at Eli Lilly, Global Clinical Research Director at Sanofi, and Global R&D Vice President and Head of R&D for Asia-Pacific at Sanofi, among other roles. From 2016 to 2022, he served as Founder and Chief Executive Officer of Cornerstone Pharmaceuticals, Executive Director, and Chairman of the Board. He joined Hengrui in January 2023 as Chief Strategy Officer and was nominated as a director and Vice General Manager. He has served as a director since February 2023 and served as Vice General Manager from February 2023 to December 2024. Since December 2024, he has served as Executive Vice President. His salary increased by RMB 0.1536 million compared with RMB 4.2527 million in 2024.

TOP 1 President Feng Ji

Pre-tax annual salary: RMB 6.5362 million

He previously worked at Shanghai Renji Hospital, Novartis, and AstraZeneca. During more than 20 years at AstraZeneca, he held roles such as Vice President of the Cardiovascular Drug Business Unit in China, Vice President in the fields of Global Infection, Central Nervous System and Immunotherapy, General Manager for China, Senior Vice President for the Asia-Pacific region, and Senior Vice President for Global Business Insights and Excellence Business, among others. He joined Hengrui in April 2025 and serves as General Manager (President) of the company and Chief Operating Officer.

A large amount of information and precise analysis—everything is on the Sina Finance APP